secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001493152-26-018302
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M
--------------------------------------------------------------------------------

- Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
- Raised $6.9M via convertible notes (10% interest, 18-month, $0.60 conversion) and warrants (5-year, $0.80 strike) to fund the deal.
- Strategic partner Sequence LifeScience invests $5.5M; will serve as contract manufacturer and collaborate on new products.
- Transaction expected to triple annual revenue to ~$35M pro-forma and be immediately accretive to profitability.
- Launched BioNX Surgical division; planned 510(k) filings in 2026, 2027, 2028 for three new products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-018302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer